Dr. Hsieh specializes in treating kidney cancers. Hence, the Hsieh laboratory primarily focuses its efforts on translational kidney cancer research. The MSKCC translational kidney cancer program primarily utilizes patient materials to directly decode the molecular basis underlying tumorigenesis, treatment response, tumor heterogeneity, and cancer metastasis, and thereby offers personalized treatment regimens. We employ state-of-art research platforms to interrogate kidney cancer genomics, proteomics, and metabolomics. Furthermore, through building the molecular blueprint of kidney cancer pathogenesis, we wish to develop novel mechanism-based therapeutics to better treat and eventually cure kidney cancer patients.
To facilitate the personalized cancer medicine for kidney cancer patients, Dr. Hsieh has founded the MSKCC Translational Kidney Cancer Research Program (TKCRP) in 2011 with Drs. Motzer and Russo and the Rare Kidney Cancer Association with Mr. Tuttle in 2012. The MSKCC TKCRP serves as a platform to integrate necessary disciplines inside (such as Medicine, Surgery, Radiology, Epidemiology & Biostatistics, Computational Biology, and Human Oncology & Pathogenesis Program) and outside MSKCC (TCGA, Harvard, MDACC, UPMC, Cleveland Clinic, UCLA, UNC, Mayo Clinic and NCI). The rKCA focuses on rare kidney cancers, including, metastatic papillary, metastatic chromophobe, medullary, collecting duct, and translocation subtypes. One of our immediate goals is to establish standard care for rare kidney cancers. Dr. Hsieh also serves as a Medical and Scientific Steering Committee Member of the Kidney Cancer Association (KCA).
In addition to the new research direction on kidney cancer, the laboratory of James Hsieh continues studying Taspase1, a protease, cloned by the Hsieh laboratory. The discovery of Taspase1 initiated a novel class of endopeptidases. Taspase1 is an evolutionarily conserved protease which cleaves nuclear factors MLL and TFIIA to orchestrate fundamental biological events. Taspase1 dictates cell fate, cell cycle, and stem and cancer cell biology, and functions as a non-oncogene addiction protease. Accordingly, the Hsieh laboratory also collaborates with the Chemical Biology Consortium (CBC) through NCI/NExT program to develop Taspase1 inhibitors for cancer therapeutics.
Chen DY, Lee Y, Van Tine BA, Searleman AC, Westergard TD, Liu H, Tu HC, Takeda S, Dong Y, Piwnica-Worms DR, Oh KJ, Korsmeyer SJ, Hermone A, Gussio R, Shoemaker RH, Cheng EH, Hsieh JJ. 2012 A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth. Cancer Research, 72(3), 736-746.
Hakimi A, Chen Y, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, Voss MH, Motzer RJ, Coleman JA, Cheng EH, Russo P, and Hsieh JJ. Clinical and Pathologic Impact of Select Chromatin Modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. European Urology, 2012, 63, 848-854.
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Vanharanta S, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J. Nat Med. 2012. 19, 50-56.
PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis. Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, Cheng EH. Sci Signal. 2013 Mar 26;6(268):ra20. doi: 10.1126/scisignal.2003483.
Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: a Report by MSKCC and the KIRC TCGA Research Network.Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen Y, Gonen M, Liu H, Takeda S, Voss MH, Tickoo SK, Reuter VE, Russo P, Cheng EH, Sander C, Motzer RJ, and Hsieh JJ for The ccRCC Cancer Genome Atlas (KIRC TCGA) Research Network investigators. Clin Can Res. 2013, 19, 3259-67.
Johns Hopkins Young Investigator Award (1996)
HHMI Physician Scientist Award (2000)
NCI Howard Temin Award (2003)
Cloned Taspase1, a Novel Protease (2003)
Scholar Award, American Society of Hematology (2006)
Scholar Award, American Cancer Society (2009)
Member, American Society for Clinical Investigation (2010)
Founder/Director, the MSKCC Translational Kidney Cancer Research Program (2011)
Committee Member, Manhattan Institute, Project FDA (2013)
Steering Committee Member, Kidney Cancer Association (2015)